References
- Murphy MA, Murphy JF. Amiodarone and optic neuropathy: the heart of the matter. J Neuroophthalmol 2005;25:232–236.
- Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol 1999;84:37R–45R.
- Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298:1312–1322.
- Vamos M, Hohnloser SH. Amiodarone and dronedarone: an update. Trends Cardiovasc Med 2016;26:597–602.
- Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975–983.
- Johnson LN, Krohel GB, Thomas ER. The clinical spectrum of amiodarone-associated optic neuropathy. J Natl Med Assoc 2004;96:1477–1491.
- Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984;34:669–671.
- Maqdasy S, Batisse-Lignier M, Auclair C, Desbiez F, Citron B, Thieblot P, Roche B, Lusson JR, Tauveron I. Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction. Am J Cardiol 2016;117:1112–1116.
- Zhong B, Wang Y, Zhang G, Wang Z. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid. Cardiology 2016;134:366–371.
- Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982;66:676–679.
- Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42:360–366.
- Flach AJ, Dolan BJ. Amiodarone-induced lens opacities: an 8-year follow-up study. Arch Ophthalmol 1990;108:1668–1669.
- Thystrup JD, Fledelius HC. Retinal maculopathy possibly associated with amiodarone medication. Acta Ophthalmol (Copenh) 1994;72:639–641.
- Younge BR. Amiodarone and ischemic optic neuropathy. J Neuroophthalmol 2007;27:85–86.
- Mindel JS. Amiodarone and optic neuropathy. Am Heart J 2008;156:411–413.
- Hayreh SS. Amiodarone, erectile dysfunction drugs, and non-arteritic ischemic optic neuropathy. J Neuroophthalmol 2006;26:154–155.
- Mansour AM, Puklin JE, O’Grady R. Optic nerve ultrastructure following amiodarone therapy. J Clin Neuroophthalmol 1988;8:231–237.
- Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999;127:610–612.
- Passman RS, Bennett CL, Purpura JM, Kapur R, Johnson LN, Raisch DW, West DP, Edwards BJ, Belknap SM, Liebling DB, Fisher MJ, Samaras AT, Jones LG, Tulas KM, McKoy JM. Amiodarone-associated optic neuropathy: a critical review. Am J Med 2012;125:447–453.
- Nagra PK, Foroozan R, Savino PJ, Castillo I, Sergott RC. Amiodarone induced optic neuropathy. Br J Ophthalmol 2003;87:420–422.
- Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984;9:136–156.
- Purvin V, Kawasaki A, Borruat FX. Optic neuropathy in patients using amiodarone. Arch Ophthalmol 2006;124:696–701.
- Mindel JS, Anderson J, Hellkamp A, Johnson G, Poole JE, Mark DB, Lee KL, Bardy GH, the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Absence of bilateral vision loss from amiodarone: a randomized trial. Am Heart J 2007;153:837–842.
- Cheng HC, Yeh HJ, Huang N, Chou YJ, Yen MY, Wang AG. Amiodarone-associated optic neuropathy: a nationwide study. Ophthalmology 2015;122:2553–2559.
- Luneau K, Newman NJ, Biousse V. Ischemic optic neuropathies. Neurologist 2008;14:341–354.
- Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133:1637–1644.
- Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, Thibault B, Rivard L, Gula L, Leong-Sit P, Essebag V, Nery PB, Tung SK, Raymond JM, Sterns LD, Veenhuyzen GD, Healey JS, Redfearn D, Roux JF, Tang AS. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;375:111–121.